Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute... (and AZ-002(Staccato alprazolam) for the ...)

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

Date:6/9/2008

and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the potential timing of the announcement of results of the AZ-004 Phase 3 clinical trial, potential benefits of AZ-004, future development of the Company's product candidates and safety of the Company's products and technologies. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)

Post Your Comments:

(Date:12/15/2009)... the newly formed industry, community and education initiative to ... County, is working to connect the orthopedics capital of ... via high-speed rail. ,, In a September report, ... the World -- An overview, analysis and blueprint ... the statewide initiative to grow Indiana,s unique life sciences ...

(Date:12/15/2009)... Flextronics (Nasdaq: ... completed the previously announced acquisition of SloMedical ... medical devices ranging from tubing sets to ... medical segment, Flextronics provides a broad set ... and pharmaceutical customers. Terms of the deal ...

(Date:12/15/2009)... -- Today,s New York Times ... Drugs Spurs Division," illustrates an internal renal community ... continuing to be deprived of their life-saving immunosuppressive ... ,, As Congress is poised to approve this ... of transplant kidney recipients, behind-the-scenes debate continues within ...

[0] OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland [0] Flextronics Completes SloMedical Acquisition [0] AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate

... Opportunity Remains for an Antiplatelet Therapy that, Combined, ... of Plavix/Iscover and Aspirin, ... WALTHAM, Mass., May 15 Decision Resources, ... for pharmaceutical and,healthcare issues, finds that Daiichi Sankyo/Eli ...

... in third quarter ... -, ... company focused on the development of,compounds for the treatment of cardiovascular disease, announced ... ACS study is one of three Phase 2 trials investigating VIA-2291,the company,s lead ...

Other Medicine Technology:Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2 Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3 VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2 VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3 VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4 VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5

Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial

(Date:12/15/2009)... -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, ... shareholders had approved all three resolutions that the Company had proposed at the Annual General ... Description of ... Votes Non-, ... For ...

(Date:12/15/2009)... Our Lady of Lourdes Health Care Services Inc., the ... to pay the United States $7.95 million to resolve ... announced today. The two hospitals are Our Lady of ... Medical Center of Burlington County (LMC) in Willingboro, N.J. ... brought by a whistleblower, Tony Kite, in 2005. The ...

(Date:12/15/2009)... 800,000 doses have lower strength than needed for protection, ... Almost 800,000 children,s doses of H1N1 swine flu vaccine ... they have lost some potency, federal health officials said ... Control and Prevention, the company,s routine testing of the ... years found that four batches had lower than required ...

(Date:12/15/2009)... 15 4R Systems, Inc., a leading ... which help retailers significantly increase profits by optimizing ... today that The Vitamin Shoppe has been utilizing ... store and DC inventory solutions have helped us ... in-stocks over the last two years," said Tony ...

(Date:12/15/2009)... North American application activity for individually underwritten life ... the MIB Life Index(SM) . Solid ... three months have lifted year-to-date (YTD) figures from ... at November,s close, -0.1%. "It is clear ... available from life insurance," says Stacy Gill, MIB ...

Breaking Medicine News(10 mins):Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2 Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3 Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2 Health News:Large Recall of Children's Swine Flu Vaccine 2 Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2 Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3 Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4 Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2 Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3

[0] Senetek PLC Announces 2009 Annual General Meeting Voting Results [0] Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations [0] Large Recall of Children's Swine Flu Vaccine [1] 4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance [1] MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November

... 11-17, is National Hospital,Week. Texas Gov. Rick Perry ... Texas, May 9 As hospitals across the,country ... the Texas,Hospital Association is emphasizing patient-focused resources available,through ... advance directives.,Consumers can visit http://www.texashospitalsonline.info to ...

... 9 Tim Booth, a 20-year health,care veteran, ... of PrePak Systems,Inc., a turnkey pharmaceutical packaging company ... week by the company,s parent, PrePak,Holdings, which is ... with financial support from its largest shareholders, Enhanced,Equity ...

... PHOENIX, May 9 CIGNA HealthCare of ... that effective immediately, CIGNA plan,members will have ... provided by,Catholic Healthcare West facilities and providers. ... hospitals, including St. Joseph,s,Hospital and Medical Center, ...

... Almost Family, Inc.,(Nasdaq: AFAM ), a ... announced that the underwriter of the public offering ... 262,500,additional shares of common stock at the public ... the Company sold 2,512,500 shares,in the offering for ...

... study finds overall 25% drop in those who take up ... influential students to spread anti-smoking messages in their everyday conversations ... study. , The study included almost 11,000 ... England and Wales. At 30 of the schools, certain students ...

... depression and many other diseases, researchers say , , ... class of drugs called vaptans may be able ... painful periods, brain hemorrhage, psychotic disorders and glaucoma, ... antagonists, work by targeting the vasopressin hormone system, ...

Other Medicine News:Health News:Web Site Helps Patients Prepare for Hospital Stay 2 Health News:Web Site Helps Patients Prepare for Hospital Stay 3 Health News:Booth Joins PrePak Systems for Growth, Expansion 2 Health News:CIGNA HealthCare of Arizona and Catholic Healthcare West Reach Agreement 2 Health News:Almost Family, Inc. Announces Exercise of Over-Allotment Option 2 Health News:Training Student Leaders Cuts Peers' Smoking Rates 2 Health News:New Class of Drugs Might Treat Many Conditions 2

Web Site Helps Patients Prepare for Hospital Stay Booth Joins PrePak Systems for Growth, Expansion CIGNA HealthCare of Arizona and Catholic Healthcare West Reach Agreement Almost Family, Inc. Announces Exercise of Over-Allotment Option Training Student Leaders Cuts Peers' Smoking Rates New Class of Drugs Might Treat Many Conditions

... The 1296-041 DELFIA Plate Dispense ... of liquids to all wells or ... microtitration plate. To minimize background and ... speeds are optimized for use with ...

Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...

... the latest innovation in prostate ... guidance. Combining 3-D image acquisition ... new technology helps physicians plan ... -- potentially improving patients' cancer ...

... 96-Well GeneAmp PCR System 9700 ... Gold-plated silver blocks for high speed 5C/sec ... blocks designed for routine PCR and cycle sequencing ... The 96-Well GeneAmp PCR System 9700 ...

Medicine Products:

1296-041 DELFIA Plate Dispense Multidrop DW (Deep Well) (220-240 V)TargetScan Targeted Prostate Biopsy System Silver 96-Well GeneAmp PCR System 9700

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute...(and AZ-002(Staccato alprazolam) for the ...),Health